Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 12th International AIDS Conference
Session 389/32406: Protease Inhibitors (PI) in the HIV+ Homeless and Marginally Housed (H/M): Good Adherence but Rarely Prescribed

July 1, 1998

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Combination therapy with PIs is often withheld from poor or marginalized populations because of a biased assumption that adherence to therapy in this group of people will be poor. In addition to this assumption about the urban poor, there is the ethical quandary between a caregivers obligation to treat a patient, and a justified fear of inviting resistance via non-adherence.

This study looked at the prevalence of PI use (in combination with nukes), the level of viral suppression after use of PIs, subsequent resistance, and adherence to PI therapy. The study enrolled 153 economically disadvantaged HIV+ patients, recruited from San Francisco homeless shelters, free food lunch lines, and single room occupancy (SRO) hotels that cost under $400 a month. Bangsberg and colleagues measured baseline antiretroviral regimens, viral load after 1-3 months on therapy, proportion of patients who reached undetectable at 3-9 months, and any viral resistance.

Perhaps the most significant finding of this study is that after 20 months, the patients had attended 91% of all scheduled clinic visits. This contradicts the general bias -- held by many -- that poor people tend to be unreliable in keeping doctors' appointments.

PI use in the cohort rose dramatically over the study period. During July-September 1996, 3% of patients were on a protease-containing regimen; by January-March 1998 that number had risen to 26%. However, the total percentage of patients on any type of antiretroviral therapy never reached 50%.

Among patients on PIs, the mean viral load reduction after three months of therapy was 1.2 log. Only 30-40% of patients became undetectable in the 3-9 month follow-up period. This is generally a lower percentage than one would predict. This anomaly, according to the researchers, cannot be attributed solely to the emergence of viral resistance, since the resistance testing performed indicated that common mutations generally were not present in these patients.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Reference

Abstract: Protease Inhibitors (PI) in the HIV+ Homeless and Marginally Housed (H/M): Good Adherence but Rarely Prescribed
Authored by: David Bangsberg, et al

Affiliations: University of California at San Francisco

See Also
6 Reasons Why People Skip Their HIV Meds
Word on the Street: Advice on Adhering to HIV Treatment
More HIV Treatment Adherence Research



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement